1.Ling Mei, Anna Schwendeman* et al. Synthetic high-density lipoprotein nanoparticles delivering rapamycin for the treatment of age-related macular degeneration. Nanomed-Nanotechnology, 2022 (44).
2.Ling Mei, Qin He* et al. Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes. J Control Release, 2018 (292):67-77.
3.Ling Mei, Qin He* et al. Enhanced tumor retention effect by click chemistry for improved cancer immunochemotherapy. ACS Appl Mater Inter, 2018, 10(21):17582-17593.
4.Ling Mei, Qin He*, et al. Polymer−drug nanoparticles combine doxorubicin carrier and heparin bioactivity functionalities for primary and metastatic cancer treatment. Mol Pharm, 2017, 14(2):513-522.
5.Ling Mei, Qin He*, et al. Antitumor and antimetastasis activities of heparin-based micelle served as both carrier and drug. ACS Appl Mater Inter, 2016, 8(15):9577-9589.
6.Ling Mei, Qin He*, et al. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin. J Control Release, 2014 (196):324-331.
7.Ling Mei, Huile Gao * et al. Angiopep-2 and activatable cell penetrating peptide dual modified nanoparticles for enhanced tumor targeting and penetrating. Int J Pharm, 2014, 474(1-2):95-102
8.Ling Mei, Ling Fu, Qin He*, et al. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. Int J Pharm, 2014, 468(1-2):26-38.
主持：
美国心脏协会博士后项目 Synthetic high-density lipoprotein mediated delivery of bioactive lipids for the treatment of cardiovascular disease. 2020.1-2021.12
联合开展2022年眉山市科技局科研项目 纳米粒调控自噬增强化疗诱导的抗肿瘤免疫应答在三阴性乳腺癌治疗中的应用 2022.8-2023.7
曾参与：
国家自然科学基金
高效原位瘤及淋巴转移瘤靶向的可变粒径纳米递药系统的研究，2018.1-2021.12
基于粒径智能化调控及程序性释放自噬抑制剂和化疗药物的纳米传递系统的构建及评价，2016.1- 2019.12
基于"一头多效"靶头高效跨越肿瘤递药屏障的脂质体给药系统的构建及评价，2014.1-2017.12
横项课题
利奈唑胺葡萄糖注射液的处方及工艺研究
利奈唑胺片的处方及工艺研究
蜀ICP备10000600号
